{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:41:58Z","timestamp":1790023318093,"version":"4.0.1"},"reference-count":40,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008108","name":"Taipei Tzu-Chi Hospital, Taiwan","doi-asserted-by":"publisher","award":["TCRD-TPE-111-10"],"award-info":[{"award-number":["TCRD-TPE-111-10"]}],"id":[{"id":"10.13039\/501100008108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Most patients with epithelial ovarian cancers (EOCs) are at advanced stages (stage III\u2013IV), for which the recurrence rate is high and the 5-year survival rate is low. The most effective treatment for advanced diseases involves a debulking surgery followed by adjuvant intravenous chemotherapy with carboplatin and paclitaxel. Nevertheless, systemic treatment with intravenous chemotherapeutic agents for peritoneal metastasis appears to be less effective due to the poor blood supply to the peritoneal surface with low drug penetration into tumor nodules. Based on this reason, hyperthermic intraperitoneal chemotherapy (HIPEC) emerges as a new therapeutic alternative. By convection and diffusion, the hyperthermic chemotherapeutic agents can directly contact intraperitoneal tumors and produce cytotoxicity. In a two-compartment model, the peritoneal\u2013plasma barrier blocks the leakage of chemotherapeutic agents from peritoneal cavity and tumor tissues to local vessels, thus maintaining a higher concentration of chemotherapeutic agents within the tumor tissues to facilitate tumor apoptosis and a lower concentration of chemotherapeutic agents within the local vessels to decrease systemic toxicity. In this review, we discuss the molecular and cellular mechanisms of HIPEC actions and the effects on EOCs, including the progression-free survival (PFS), disease-free survival (DFS) and overall survival (OS). For primary advanced ovarian cancers, more studies are agreeing that patients undergoing HIPEC have better surgical and clinical (PFS; OS) outcomes than those not, although one study reported no differences in the PFS and OS. For recurrent ovarian cancers, studies have revealed better DFS and OS in patients undergoing HIPEC than those in patients not undergoing HIPEC, although one study reported no differences in the PFS. HIPEC appears comparable to traditional intravenous chemotherapy in treating advanced EOCs. Overall, HIPEC has demonstrated some therapeutic benefits in many randomized phase III trials when combined with the standard cytoreductive surgeries for advanced EOCs. Nevertheless, many unknown aspects of HIPEC, including detailed mechanisms of actions, along with the effectiveness and safety for the treatment of EOCs, warrant further investigation.<\/jats:p>","DOI":"10.3390\/ijms231710078","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T05:17:23Z","timestamp":1662441443000},"page":"10078","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers"],"prefix":"10.3390","volume":"23","author":[{"given":"Pei-Qi","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Medical Education, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei 231, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-3788","authenticated-orcid":false,"given":"I-Hung","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei 231, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kok-Min","family":"Seow","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei 111, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Yang-Ming Chiao-Tung University, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4758-0351","authenticated-orcid":false,"given":"Kuo-Hu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei 231, Taiwan"},{"name":"School of Medicine, Tzu-Chi University, Hualien 970, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global Cancer Statistics, 2012. CA","volume":"65","author":"Torre","year":"2015","journal-title":"Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1002\/cncr.32505","article-title":"Hyperthermic Intraperitoneal Chemotherapy for Ovarian Cancer: The Heat Is On","volume":"125","author":"Koole","year":"2019","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0032-1328320","article-title":"Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer","volume":"73","author":"Harter","year":"2013","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ceelen, W., Demuytere, J., and de Hingh, I. (2021). Hyperthermic Intraperitoneal Chemotherapy: A Critical Review. Cancers, 13.","DOI":"10.20944\/preprints202105.0084.v1"},{"key":"ref_6","first-page":"45","article-title":"Chemotherapy for Intraperitoneal Use: A Review of Hyperthermic Intraperitoneal Chemotherapy and Early Post-Operative Intraperitoneal Chemotherapy","volume":"7","author":"Goodman","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Riggs, M.J., Pandalai, P.K., Kim, J., and Dietrich, C.S. (2020). Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Diagnostics, 10.","DOI":"10.3390\/diagnostics10010043"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1525-1438.2007.01099.x","article-title":"Pharmacologic Principles of Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer","volume":"18","author":"Howell","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/02656736.2017.1291999","article-title":"Drugs, Doses, and Durations of Intraperitoneal Chemotherapy: Standardising HIPEC and EPIC for Colorectal, Appendiceal, Gastric, Ovarian Peritoneal Surface Malignancies and Peritoneal Mesothelioma","volume":"33","author":"Lemoine","year":"2017","journal-title":"Int. J. Hyperth."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/11598890-000000000-00000","article-title":"Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics","volume":"51","author":"Hasovits","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"153473541987634","DOI":"10.1177\/1534735419876345","article-title":"The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors","volume":"18","author":"Cheng","year":"2019","journal-title":"Integr. Cancer Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gallego-Jara, J., Lozano-Terol, G., Sola-Mart\u00ednez, R.A., C\u00e1novas-D\u00edaz, M., and de Diego Puente, T. (2020). A Compressive Review about Taxol\u00ae: History and Future Challenges. Molecules, 25.","DOI":"10.3390\/molecules25245986"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J","article-title":"Paclitaxel-Induced Cell Death: Where the Cell Cycle and Apoptosis Come Together","volume":"88","author":"Wang","year":"2000","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in Cancer Therapy: Molecular Mechanisms of Action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2478\/raon-2019-0018","article-title":"Cisplatin and beyond: Molecular Mechanisms of Action and Drug Resistance Development in Cancer Chemotherapy","volume":"53","author":"Makovec","year":"2019","journal-title":"Radiol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13048-019-0509-1","article-title":"The Prognosis Impact of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) plus Cytoreductive Surgery (CRS) in Advanced Ovarian Cancer: The Meta-Analysis","volume":"12","author":"Zhang","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/JCO.2017.35.15_suppl.5520","article-title":"Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women with Primary Advanced Peritoneal, Ovarian, and Tubal Cancer","volume":"35","author":"Lim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ajo.13297","article-title":"HIPEC: Turning up the Heat on Ovarian Cancer","volume":"61","author":"Farrell","year":"2021","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2013940","DOI":"10.1001\/jamanetworkopen.2020.13940","article-title":"Chinese Peritoneal Oncology Study Group (Gynecologic Oncology Study Group). Evaluation of Cytoreductive Surgery with or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer","volume":"3","author":"Lei","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejso.2011.03.134","article-title":"Perioperative Fast Track Program in Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery in Advanced Ovarian Cancer","volume":"37","year":"2011","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2014.11.072","article-title":"A Critical Appraisal of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Advanced and Recurrent Ovarian Cancer","volume":"136","author":"Chiva","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/02656736.2020.1795277","article-title":"Sodium Thiosulfate Protects from Renal Impairement Following Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin","volume":"37","author":"Laplace","year":"2020","journal-title":"Int. J. Hyperth."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ejso.2015.12.016","article-title":"Assessment of RIFLE and AKIN Criteria to Define Acute Renal Dysfunction for HIPEC Procedures for Ovarian and Non Ovarian Peritoneal Malignances","volume":"42","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ejso.2016.09.008","article-title":"Best Practice for Perioperative Management of Patients with Cytoreductive Surgery and HIPEC","volume":"43","author":"Schneider","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejso.2019.05.006","article-title":"Health-Related Quality of Life after Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Stage III Ovarian Cancer","volume":"47","author":"Koole","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/jog.14391","article-title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gynecological Cancer","volume":"46","author":"Tsuyoshi","year":"2020","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jss.2018.08.018","article-title":"Non-Home Discharge and Prolonged Length of Stay After Cytoreductive Surgery and HIPEC","volume":"233","author":"Burguete","year":"2019","journal-title":"J. Surg. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1016\/j.ejso.2021.04.004","article-title":"Short-Term Outcomes in Older Patients with Peritoneal Malignancy Treated with Cytoreductive Surgery and HIPEC: Experience with 245 Patients from a National Centre","volume":"47","author":"Keyes","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2020.11.035","article-title":"HIPEC after Neoadjuvant Chemotherapy and Interval Debulking Is Associated with Development of Platinum-Refractory or -Resistant Disease","volume":"161","author":"Jou","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for FIGO Stage III Epithelial Ovarian Cancer: OVHIPEC-2, a Phase III Randomized Clinical Trial","volume":"30","author":"Koole","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2020.12.029","article-title":"State of the Science: The Role of HIPEC in the Treatment of Ovarian Cancer","volume":"160","author":"Dellinger","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1002\/cncr.33163","article-title":"Intraperitoneal Chemotherapy: Hot, Timely, and Relevant?","volume":"126","author":"Mackay","year":"2020","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1002\/cncr.32496","article-title":"Hyperthermic Intraperitoneal Chemotherapy Does Not Improve Survival in Advanced Ovarian Cancer","volume":"125","author":"Vergote","year":"2019","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.19.00091","article-title":"Is There a Role for Intraperitoneal Chemotherapy, Including HIPEC, in the Management of Ovarian Cancer?","volume":"37","author":"Vergote","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2018.07.019","article-title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Is Cost-Effective in the Management of Primary Ovarian Cancer","volume":"151","author":"Behbakht","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1200\/JCO.19.00594","article-title":"Cost Effectiveness of Interval Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial","volume":"37","author":"Koole","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.suronc.2016.06.001","article-title":"Operating Personnel Safety during the Administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC)","volume":"25","author":"Kyriazanos","year":"2016","journal-title":"Surg. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/17\/10078\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:22:53Z","timestamp":1760142173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/17\/10078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":40,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijms231710078"],"URL":"https:\/\/doi.org\/10.3390\/ijms231710078","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,3]]}}}